Patient P-02574

Synthetic patientMETA-24 · Day 170 · 45–54 · F · baseline S14Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

89%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 75 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 81 ME-01 recommended — Monitoring Escalation ME-01
Day 82 Patient accepted — Started ME-01 in the companion
Day 85 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 75.

Primary contributors, last 14 days

GI instability-7
Inflammatory activity-5
Nutritional resilience+5
Treatment adherence-3

What helped?

Monitoring Escalation ME-01Day 81
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 54
- WearableHRV 24 ms, trending down
Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 54 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑65
- WearableResting HR 82 bpm
- Wearable300 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 48

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.3 · butyrate capacity 25/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 20 ms
Sleep: 6.2 h
Steps: 711
Resting HR: 85 bpm

Daily log: GI score 54, nutritional resilience 40, adherence 41.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02268	60%	S14	GI-04	improved	43
P-02363	57%	S14	GI-04	improved	49
P-02014	56%	S14	GI-04	improved	48
P-02132	56%	S14	SC-12	improved	40
P-02633	56%	S14	NP-02	improved	48
P-02118	55%	S14	GI-04	improved	47
P-02628	55%	S14	SC-12	improved	47
P-02693	54%	S14	ME-01	improved	41
P-02348	53%	S14	GI-04	improved	49
P-02535	53%	S14	SC-12	improved	50
P-02253	52%	S14	NP-02	no change	41
P-02057	51%	S14	GI-04	improved	47